Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
09/2014
09/02/2014US8822518 Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction
09/02/2014US8822492 Use of huperzine for disorders
09/02/2014US8822479 6-cyclylmethyl-and 6-alkylmethyl-substituted pyrazolepyrimidines
09/02/2014US8822474 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases
09/02/2014US8822458 Substituted oxazolidinones and their use in the field of blood coagulation
09/02/2014US8822449 Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
09/02/2014US8822437 Cerebral nerve cell neogenesis agent
09/02/2014US8821920 Therapeutic patch for transdermal delivery of capsaicin
08/2014
08/28/2014WO2014130894A1 Compositions for the treatment of inflammatory diseases
08/28/2014WO2014130581A1 Acth for treatment of migraine headache
08/28/2014WO2014130258A1 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1)
08/28/2014WO2014129990A1 1 -(dimethylamino)ethyl-substituted 6h-benzo[c]chromen-6-ones against senile dementia
08/28/2014WO2014129989A1 3-substituted-6h-benzo[c]chromen-6-ones and 3-substituted-7,8,9,10-tetrahydro-6h-benzo[c]chromen-6-ones against senile dementia
08/28/2014WO2014129744A1 Four-membered cyclic nitrogen compound, pharmaceutical composition for preventing or treating depression, mental disorders, premature ejaculation or neuropathic pain, containing same, and preparation containing pharmaceutical composition
08/28/2014WO2014128585A1 Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
08/28/2014WO2014128486A1 Pyrimidine compounds useful in the treatment of diseases mediated by ikke and/or tbk1 mechanisms
08/28/2014WO2014128259A1 Pharmaceutical composition for the treatment of burnout syndrome
08/28/2014WO2014128254A1 Il-33 and treatment of neurodegenerative diseases
08/28/2014WO2014128223A1 Pyridine derivatives as 5-ht6 receptor antagonists
08/28/2014WO2014127459A1 Pharmaceutical composition for enhanced transmucosal administration of benzodiazepines
08/28/2014WO2014127458A1 Pharmaceutical composition for transmucosal administration of benzodiazepines
08/28/2014US20140243284 Biologically active macrolides, compositions, and uses thereof
08/28/2014US20140242691 Neural Progenitor Cell Populations
08/28/2014US20140242166 Sustained release matrix systems for highly soluble drugs
08/28/2014US20140242086 Polynucleotides encoding signal peptide-containing molecules
08/28/2014DE112012005185T5 Transdermales Verabreichungssystem The transdermal delivery system
08/27/2014EP2769980A1 Pyrazoloquinoline derivative
08/27/2014EP2769976A1 Hydroxamic acid compound containing quinolyl and preparation method thereof, and pharmaceutical composition containing this compound and use thereof
08/27/2014EP2769736A1 Pharmaceutical composition for the treatment of burnout syndrome
08/27/2014EP2769718A1 Medicinal composition
08/27/2014EP2769717A1 A composition comprising reduced glutathione and acetaminophen and preparation method thereof
08/27/2014EP2769716A1 Pharmaceutical composition comprising fluoxetine as an active ingredient, for preventing or treating blood-brain barrier disorders
08/27/2014EP2769715A2 Methods for treating autoimmune disorders, and reagents related thereto
08/27/2014EP2769713A1 Solid oral composition comprising a S1P receptor agonist and a sugar alcohol
08/27/2014EP2768823A1 2-pyridyloxy-4-nitrile orexin receptor antagonists
08/27/2014EP2768821A1 Solid forms of 1,l-dioxo-4-thiomorpholinyl)-[6-[[3(4-fluorophenyl)-5-methyl-4-isoxazolyl]methoxy]-3-pyridinyl]-methanone
08/27/2014EP2768513A2 Use of avermectin derivative for increasing bioavailability and efficacy of macrocylic lactones
08/27/2014EP2768507A2 Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
08/26/2014US8815944 Pharmaceutical composition with gelling properties containing a tyrosine derivative
08/26/2014US8815939 Substituted sulfamide derivatives
08/26/2014US8815905 Propionic acids, propionic acid esters, and related compounds
08/26/2014US8815801 Controlled release composition and method of producing the same
08/26/2014US8815293 Organic compounds
08/26/2014US8815287 Opiod agonist formulations with releasable and sequestered antagonist
08/26/2014US8815261 Composition for external application comprising aripiprazole and organic acid as active ingredients
08/26/2014CA2630655C Isoquinoline et benzo[h]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine h3 receptor
08/21/2014WO2014127360A1 Pcl compounds, compositions, and methods of use thereof
08/21/2014WO2014127315A1 Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them
08/21/2014WO2014127201A1 Neuroactive enantiomeric 15-, 16- and 17-substituted steroids as modulators for gaba type-a receptors
08/21/2014WO2014127139A1 Treatment of multiple sclerosis with laquinimod
08/21/2014WO2014127042A1 Hydantoins that modulate bace-mediated app processing
08/21/2014WO2014126979A1 Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
08/21/2014WO2014126972A1 Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy
08/21/2014WO2014126596A1 Neuroprotective multifunctional antioxidants and their monofunctional analogs
08/21/2014WO2014126486A1 Pharmacological indications and uses of preparations from dioscorea hispida
08/21/2014WO2014125444A1 Heterocyclic amides as kinase inhibitors
08/21/2014WO2014125397A1 SUBSTITUTED PHENYL HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
08/21/2014WO2014125340A1 Smoke liquid for atomizers and/or vaporizers
08/21/2014WO2014125277A1 Method of producing microparticles
08/21/2014WO2014125276A1 Stem cell microparticles and mirna
08/21/2014WO2014125256A1 Nanoparticle delivery compositions
08/21/2014WO2014125121A1 Compounds and compositions for treating neurodegenerative diseases
08/21/2014WO2014124651A1 Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
08/21/2014WO2014124560A1 Mglur regulators
08/21/2014WO2014102778A3 Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same
08/21/2014WO2014100600A3 Human anti-tau antibodies
08/21/2014WO2014091388A3 Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
08/21/2014WO2014089209A3 Blood-brain barrier (bbb) penetrating dual specific binding proteins
08/21/2014WO2014087298A4 Novel selective androgen receptor modulators
08/21/2014US20140235564 Methods for treating neural cell swelling
08/21/2014DE10066235C5 Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens Method and medicament for the inhibition of expression of a given gene
08/20/2014EP2767536A1 Isoxazolo-pyridine derivatives
08/20/2014EP2767533A1 Derivative of butylphthalide and preparation method and use thereof
08/20/2014EP2767532A1 Novel compound for imaging tau protein accumulated in the brain
08/20/2014EP2767310A1 Methods Of Reduction Of Interpatient Variability
08/20/2014EP2767287A1 Agent for preventing or treating htlv-i associated myelopathy
08/20/2014EP2767283A1 Therapeutic agent and preventive agent for demyelinating disease
08/20/2014EP2766495A1 Method of diagnosis, prognostic or treatment of neurodegenerative diseases
08/20/2014EP2766482A1 Micrornas in neurodegenerative disorders
08/20/2014EP2766380A1 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
08/20/2014EP2766360A1 Soluble guanylate cyclase activators
08/20/2014EP2766358A1 Novel oxazine derivatives and their use in the treatment of disease
08/20/2014EP2766353A1 2-oxo-piperidinyl derivatives
08/20/2014EP2766339A1 The use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain
08/20/2014EP2766094A2 Compositions for binding to amyloid proteins
08/20/2014EP2766093A1 Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability
08/20/2014EP2766027A1 Raising and diagnosing of serotonin level
08/20/2014EP2766017A1 Methods for treating a stroke-related sensorimotor impairment using aminopyridines
08/20/2014EP2766003A1 Composition for the prophylactic treatment of neuropathic pain
08/20/2014EP2766002A2 R(+)-n-formyl-propargyl-aminoindan
08/20/2014EP2765985A1 Orally dispersible tablet
08/19/2014US8809525 1,2,4-triazine-4-amine derivatives
08/19/2014US8809348 6-arylmethyl substituted pyrazolo[3,4-d]pyrimidines
08/19/2014US8809345 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
08/19/2014US8809329 Detection and treatment of schizophrenia
08/19/2014US8809011 HIFα hydroxylation assay
08/19/2014US8808742 Compositions and methods for preparing and using same
08/19/2014US8808691 Method for treating tumors and their metastases
08/19/2014CA2762878C Crystalline forms of a pharmaceutical compound
08/19/2014CA2602545C Phenyl-n-acyl derivatives of amines and amino acids, a process for the preparation thereof, a pharmaceutical composition and the use thereof
1 ... 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 ... 1833